Kalvista Pharmaceuticals Inc

KALV remains in a Stage 2 advancing regime underpinned by a strong parabolic acceleration, reinforcing a bullish medium-term bias. However, price is severely extended above rising short-term EMAs with RSI and Options Score in extreme overbought territory, signaling near-term exhaustion risk. Execution should be deferred and staged on meaningful pullbacks into the rising EMA zone or the recent breakout support area.

• ↑Q1 Ectorly sales of $1.4M show strong launch demand
• ↑5% of US HAE patients submitted prescriptions within weeks
• ↓Operating expenses at $60.4M weigh on margins and cash burn